Abstract:Abstract BACKGROUND AND AIMS Chronic kidney disease (CKD) is a serious progressive disease with a substantial impact on global health that affects ∼10% of the world's population. However, CKD remains largely under-recognized. Effective actions to slow disease progression and improve outcomes depend on timely detection and diagnosis before a further decline in estimated glomerular filtration rate (eGFR). The aim of the REVEAL-CKD study is to assess the prevalence of, and factors associated with, undiagnosed early (stage 3) CKD. METHOD REVEAL-CKD is a multi-national, multi-regional observational study using secondary data from electronic medical records and claims databases. In this analysis, we extracted data regarding patient demographics, laboratory tests, diagnoses and treatments from an Italian electronic medical record database, the Italian Longitudinal Patients Database (IQVIA, Italy). The Italian Longitudinal Patients Database consists of anonymised patient records collected from routine visits to general practitioners and represents ∼900 general practitioners and 1.2 million patients across Italy. The study cohort included patients aged ≥18 years between 2015–21 with two consecutive estimated glomerular filtration rate (eGFR) results ≥30 and <60 mL/min/1.73 m2 recorded >90 and ≤730 days apart. The date of the second qualifying eGFR was defined as the index date. Patients with no presence of a CKD diagnostic code recorded any time before their first qualifying eGFR and up to 6 months after their second qualifying eGFR were considered to be undiagnosed. The prevalence of undiagnosed CKD was calculated as the ratio of undiagnosed patients to all patients who met the study inclusion criteria. RESULTS The study cohort included 65 676 patients who met the eGFR criteria for stage 3 CKD. The mean age at index date was 79 years (standard deviation: 9 years) and 58% were female. The overall prevalence of undiagnosed CKD was 77.0% [95% confidence interval (CI): 76.6–77.3]. The prevalence of undiagnosed CKD was greater in patients with stage 3a CKD (83.0%) compared with those with stage 3b CKD (64.8%). Female patients and those aged > 65 years showed a higher prevalence of undiagnosed CKD, and the prevalence of undiagnosed CKD ranged from 66.6% to 75.7% in patients with pre-existing comorbidities (Table 1). In patients who were undiagnosed at the index date (n = 52 533), 15.5% (n = 8152) were diagnosed with CKD after the index date, with a median time to diagnosis of 404 days (IQR: 389–418 days); 84.5% (n = 44 381) remained undiagnosed. CONCLUSION This study indicates that a high proportion of patients with stage 3 CKD are undiagnosed by their general practitioners, with inequity noted for females and older patients. Underdiagnosis of CKD persisted in those with known risk factors for CKD such as diabetes, heart failure and hypertension. With the availability of targeted evidence-based therapies to decrease the risk of disease progression and improve patient outcomes, there is a clear need to proactively detect, diagnose and intervene in patients with early-stage CKD.

Development and evaluation of a kidney health questionnaire and estimates of chronic kidney disease prevalence in the Cooperative Health Research in South Tyrol (CHRIS) study

MO509: Reveal-CKD: Prevalence of Undiagnosed Stage 3 Chronic Kidney Disease Italy

Prevalence of undetected chronic kidney disease in high-risk middle-aged patients in primary care: a cross-sectional study

Clinical and Economic Impact of Early Diagnosis of Chronic Kidney Disease in General Practice: The Endorse Study

Design and methodology of the chronic kidney disease as a dysmetabolic determinant of disability among older people (CKD-3D) study: a multicenter cohort observational study

Patient and caregiver perspectives on gender disparity in chronic kidney disease: Questionnaire survey, based on an interview study

#3667 REVEAL-CKD: PREVALENCE OF UNDIAGNOSED STAGE 3 CHRONIC KIDNEY DISEASE IN AUSTRALIA, BRAZIL, CANADA AND SPAIN

Development and application of a chronic kidney disease-specific health literacy, knowledge and disease awareness assessment tool for patients with chronic kidney disease in Taiwan

The CKD bowel health study: understanding the bowel health and gastrointestinal symptom management in patients with chronic kidney disease: a mixed-methods observational longitudinal study (protocol)

The natural history of, and risk factors for, progressive Chronic Kidney Disease (CKD): the Renal Impairment in Secondary care (RIISC) study; rationale and protocol

Epidemiological Analysis in a NorthEastern District of Italy Focusing on Access to Nephrological Care

Chronic kidney disease and cardiovascular risk in six regions of the world (ISN-KDDC): a cross-sectional study.

Self-efficacy, social support and oral health-related quality of life in patients with kidney transplantation and under hemodialysis

Investigating the global prevalence and consequences of undiagnosed stage 3 chronic kidney disease: methods and rationale for the REVEAL-CKD study

Prevalence and incidence of chronic kidney disease stage 3–5 – results from KidDiCo

Proteinuria Assessment and Therapeutic Implementation in Chronic Kidney Disease Patients-A Clinical Audit on KDIGO ("Kidney Disease: Improving Global Outcomes") Guidelines

Patterns of kidney function and risk assessment in a nationwide laboratory database: the Brazilian CHECK-CKD study

A cluster-randomized study to evaluate the effectiveness and cost-effectiveness of the Assessment of Burden of Chronic Conditions (ABCC) tool in South Tyrolean primary care for patients with COPD, asthma, type 2 diabetes, and heart failure: the ABCC South Tyrol study

RENA Study: Cross-Sectional Study to Evaluate CKD Prevalence in Portugal

Screening and management of hypertensive patients with chronic kidney disease referred to Hypertension Excellence Centres among 27 countries. A pilot survey based on questionnaire.

DASH diet, Reduced Rank Regression Dietary Patterns and relations with kidney function in the CHRIS general population study